Additionally, the research demonstrated that PARPis Olaparib and Talazoparib significantly hamper the growth of prostate cancer cell lines and organoids derived from human mCRPC exhibiting both homozygous and heterozygous co-deletion of BRCA2 and RB1. Here, RB1 is linked to Familial prostate cancer.